KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Enterprise Value (2016 - 2025)

Pacific Biosciences Of California has reported Enterprise Value over the past 16 years, most recently at -$279.5 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$279.5 million for Q4 2025, up 28.32% from a year ago — trailing twelve months through Dec 2025 was -$279.5 million (up 28.32% YoY), and the annual figure for FY2025 was -$279.5 million, up 28.32%.
  • Enterprise Value for Q4 2025 was -$279.5 million at Pacific Biosciences Of California, up from -$298.7 million in the prior quarter.
  • Over the last five years, Enterprise Value for PACB hit a ceiling of -$76.9 million in Q1 2024 and a floor of -$1.1 billion in Q2 2021.
  • Median Enterprise Value over the past 5 years was -$631.4 million (2023), compared with a mean of -$609.8 million.
  • Biggest five-year swings in Enterprise Value: plummeted 1166.75% in 2021 and later surged 91.21% in 2024.
  • Pacific Biosciences Of California's Enterprise Value stood at -$1.0 billion in 2021, then increased by 26.05% to -$772.3 million in 2022, then rose by 18.24% to -$631.4 million in 2023, then surged by 38.24% to -$389.9 million in 2024, then increased by 28.32% to -$279.5 million in 2025.
  • The last three reported values for Enterprise Value were -$279.5 million (Q4 2025), -$298.7 million (Q3 2025), and -$314.7 million (Q2 2025) per Business Quant data.